Roy D. Baynes is on the board of Natera, Inc., Travere Therapeutics, Inc. and Atara Biotherapeutics, Inc. and Member of American Society of Clinical Oncology, Member of American Association for Cancer Research and Member of American Society of Hematology.

In the past Roy D. Baynes held the position of Chief Medical Officer for Merck & Co., Inc. and SVP & Head-Global Clinical Development at Merck Research Laboratories Massachusetts LLC (a subsidiary of Merck & Co., Inc.), VP-Global Development & Head-Hematology Oncology at Amgen, Inc., SVP-Oncology, Inflammation & Respiratory at Gilead Sciences, Inc. and Professor at Barbara Ann Karmanos Cancer Institute.

Dr. Baynes received a doctorate and a graduate degree from the University of the Witwatersrand.

- Keine Nachrichten -